ABSTRACT
Immune thrombocytopenia (ITP) is a common hematologic disorder. Its pathogenesis involves both accelerated platelet destruction and impaired platelet production. First-line agents are usually effective initially but do not provide long-term responses. Splenectomy remains an effective long-term therapy, as does rituximab (Rituxan) in a subset of patients. Thrombopoietic agents offer a new alternative, although their place in the overall management of ITP remains uncertain.
Footnotes
↵* The author has disclosed that he has received honoraria from GlaxoSmithKline and Amgen for teaching and speaking.
- Copyright © 2011 The Cleveland Clinic Foundation. All Rights Reserved.